Study Captures Drivers and Deterrents to Digital Health to Inform Biopharma Cx, Commercialization and Marketing Efforts

研究捕捉数字健康的驱动因素和阻碍因素，以指导生物制药公司的客户体验、商业化和营销工作。

SAN FRANCISCO

旧金山

,

，

April 1, 2025

2025年4月1日

/PRNewswire/ --

/PRNewswire/ --

ixlayer

ixlayer

, a leading cloud-based healthtech platform, with Ipsos, a global leader in market research, have released findings from the inaugural research report

，一家领先的基于云的健康科技平台，与全球市场研究领域的领导者益普索（Ipsos）共同发布了首份研究报告的调查结果。

,

，

'

'

ixlayer

ixlayer

ixInsights 2025: Pharma's Role in Improving the Health Experience.'

ixInsights 2025：制药在改善健康体验中的作用。

The study looks at patients with specific conditions–asthma, COPD, type 2 diabetes, heart disease, psoriasis, or atopic dermatitis–to identify their experiences, motivations and barriers to digital health adoption. More importantly, it looks ahead outlining actionable insight and drivers to enhance biopharma's customer experience (Cx), commercialization and marketing efforts..

该研究着眼于患有特定疾病（哮喘、慢性阻塞性肺病、2型糖尿病、心脏病、牛皮癣或特应性皮炎）的患者，以了解他们在数字健康应用方面的体验、动机和障碍。更重要的是，它展望未来，提出了可操作的见解和驱动因素，以提升生物制药领域的客户体验 (Cx)、商业化和营销工作。

To view the complete 'ixlayer ixInsights 2025' study by Ipsos, email

要查看益普索完整的《ixlayer ixInsights 2025》研究报告，请发送电子邮件至

contact@ixlayer.com

contact@ixlayer.com

to request a copy.

请求一份副本。

A resounding 74% of surveyed patients would value help from a pharmaceutical company to reduce their healthcare barriers. These findings explore the health solutions these patients are looking for and the positive impact on the perception of the pharma companies that offer them.

调查显示，高达74%的患者会重视制药公司帮助他们减少医疗障碍。这些发现探讨了这些患者正在寻找的健康解决方案，以及提供这些方案的制药公司对其形象带来的积极影响。

In fact, 8 in 10 patients in this survey said that pharmaceutical companies should provide resources to help them get the care and medicines they need (81%). The report highlights consumers' strong demand for various digital health solutions from pharma including patient assistance, affordability, easier access to lab testing, tools to help access medication and telehealth services.

事实上，这项调查中十分之八的患者表示，制药公司应提供资源，帮助他们获得所需的治疗和药物 (81%)。报告强调了消费者对制药公司提供的各种数字健康解决方案的强烈需求，包括患者援助、可负担性、更便捷的实验室检测、帮助获取药物的工具以及远程医疗服务。

Consumer sentiment aligns with the 83% of U.S. physicians across specialties that believe at-home diagnostic tests help move patients through the care continuum faster, leading to earlier diagnosis and treatment to support better health, according to a separate 2024 .

根据另一项 2024 年的研究，消费者情绪与跨专业领域 83% 的美国医生一致，他们认为家庭诊断测试有助于加快患者在护理过程中的进展，从而实现更早的诊断和治疗，以支持更好的健康状况。

survey

调查

of U.S. physicians.

美国医生。

'The expansion of DTC initiatives and services leveraging digital technology for pharma is a hot topic among the biopharma leaders we meet with, and partnering with Ipsos allowed us to uncover the real challenges and opportunities shaping the future of this emerging model,' explained

“利用数字技术进行制药业的DTC举措和服务扩展，是我们所接触的生物制药领导者们热议的话题，与益普索的合作使我们能够揭示塑造这一新兴模式未来的真正挑战和机遇，”他解释道。

Pouria Sanae

普里亚·萨纳埃

, co-founder and CEO, ixlayer. 'This survey confirms that patients don't just want treatment from pharma—they want seamless, digital-first healthcare experiences that fit into their lives.'

，联合创始人兼首席执行官，ixlayer。 “这项调查证实，患者不仅仅需要制药公司提供治疗方案——他们更希望获得能够无缝融入生活的、以数字化为主的医疗体验。”

'It is crucial for all stakeholders to focus on integrating and developing tools that put patients at the core,' explained

“所有利益相关者都必须专注于整合和开发以患者为核心工具，这一点至关重要，”他解释道。

Chareen Lim

林彩琳

, SVP of Ipsos Healthcare. 'The journey towards a seamless patient experience is ongoing, and this study shows there are ample opportunities to innovate and improve within this young and dynamic sector.'

益普索医疗保健高级副总裁。 “通往无缝患者体验的旅程正在进行中，这项研究表明在这个年轻而动态的领域中有许多创新和改进的机会。”

Excerpted data: 'ixlayer ixInsights 2025: Pharma's Role in Improving the Health Experience'

摘录数据：'ixlayer ixInsights 2025：制药在改善健康体验中的角色'

Current adoption is strong, with room for technical improvements

当前的采用情况良好，但仍有技术改进的空间。

More than 3 out of 4 respondents agree that digital health solutions have helped maintain better communication with their healthcare providers (77%)

超过四分之三的受访者认为数字健康解决方案有助于更好地与医疗服务提供者保持沟通 (77%)。

They believe that it's a cost effective way to maintain their health (73%)

他们认为这是一种具有成本效益的保健方法 (73%)

27% report having technical difficulties when using digital health solutions

27% 的人报告在使用数字健康解决方案时遇到技术困难。

50% have to use multiple digital health platforms

50% 的人必须使用多个数字健康平台

Top digital health solutions

顶级数字健康解决方案

92% of surveyed patients use or have used patient portals for accessing healthcare information and resources

92% 的受访患者使用或曾经使用过患者门户来访问医疗保健信息和资源。

82% use or have used telehealth platforms for virtual consultations

82% 使用或曾经使用过远程医疗平台进行虚拟咨询。

67% use or have used pharmacy delivery services

67% 使用或曾经使用过药店送货服务

65% use or have used wearable devices for health

65% 的人使用或曾经使用过可穿戴设备来关注健康。

62% use or have used at-home diagnostic testing kits

62% 的人使用或曾经使用过家庭诊断测试套装

These patients want pharma to do more

这些患者希望制药公司做得更多。

81% of respondents believe pharmaceutical companies should provide resources to help them access care and medications

81%的受访者认为制药公司应该提供资源，帮助他们获得医疗服务和药物。

Only 16% strongly believes pharma prioritizes their needs

只有16%的人强烈相信制药公司优先考虑他们的需求。

Attributes of digital health services poised to drive usage

数字健康服务推动使用的属性

Ability to consult with healthcare professionals virtually or schedule in person

能够虚拟咨询医疗专业人员或安排面对面预约

83% of respondents report a likelihood to use

83% 的受访者表示有可能使用

Accept insurance coverage for services

接受服务的保险覆盖范围

83% report a likelihood to use

83% 的人表示可能会使用

Secure options for sharing your health data (e.g., lab test results) with others including your healthcare provider

与他人（包括您的医疗保健提供者）分享您的健康数据（例如，实验室测试结果）的安全选项

79% report a likelihood to use

79% 的人表示有可能使用

Easier access for lab testing, at-home kits, or scheduling at service center

实验室检测、家用套装或服务中心预约更加便捷

78% report a likelihood to use

78% 的人表示有可能使用

Provides digital pharmacy options (e.g., online ordering, prescription delivery)

提供数字药房选项（例如，在线订购、处方配送）

74% report a likelihood to use

74% 的人表示有可能使用

92% of surveyed patients say their perception of pharma would improve

92%的受访患者表示，他们对制药公司的看法会有所改善。

if they offered at least one of the following digital health solutions, including:

如果他们提供以下至少一种数字健康解决方案，包括：

Ability to consult with healthcare professionals virtually or schedule in person

能够虚拟咨询医疗专业人员或安排面对面预约

78% say it would improve their perception of pharma

78%的人表示这将改善他们对制药行业的看法

Accept insurance coverage for services

接受服务的保险覆盖范围

83% say it would improve their perception of pharma

83%的人表示这将改善他们对制药行业的看法

Secure options for sharing your health data (e.g., lab test results) with others including your healthcare provider

与他人（包括您的医疗保健提供者）分享您的健康数据（例如，实验室测试结果）的安全选项

77% say it would improve their perception of pharma

77%的人表示这将改善他们对制药行业的看法

Easier access for lab testing, at-home kits, or scheduling at service center

实验室检测、家用套件或服务中心预约更容易获取

78% say it would improve their perception of pharma

78%的人表示这将改善他们对制药行业的看法

Provides digital pharmacy options (e.g., online ordering, prescription delivery)

提供数字药房选项（例如，在线订购、处方配送）

74% say it would improve their perception of pharma

74%的人表示这会改善他们对制药行业的看法

The study captures consumer sentiment for what's working and what's not in digital health. Their top reasons for satisfaction with digital health are: convenience, improved communication with healthcare providers, quicker access to treatment or care, and easier access to the medications they need. The top reasons for dissatisfaction with digital health are: the need to use multiple platforms to get what they need, technical issues, and concerns about data security..

该研究捕捉了消费者对数字健康领域中哪些措施有效、哪些无效的情感。他们对数字健康感到满意的主要原因是：便利性、与医疗保健提供者沟通的改善、更快地获得治疗或护理，以及更容易获取所需药物。对数字健康感到不满的主要原因包括：需要使用多个平台才能获得所需内容、技术问题，以及对数据安全的担忧。

The rise of digital health, telemedicine, and direct-to-patient platforms highlights the growing demand for technology-driven healthcare solutions. As consumers increasingly expect these innovations, the survey findings signal a critical opportunity for pharma to strengthen its relationship with patients.

数字健康、远程医疗和直接面向患者的平台的兴起突显了对技术驱动型医疗解决方案日益增长的需求。随着消费者对这些创新的期望不断增加，调查结果表明制药行业有一个加强与患者关系的关键机会。

Companies that prioritize.

优先考虑的公司。

patient-centric, digital solutions

以患者为中心的数字解决方案

will be well-positioned to lead in the evolving healthcare ecosystem.

将在不断发展的医疗生态系统中占据有利位置，引领发展。

About ixlayer

关于ixlayer

ixlayer [pronounced: I-X-layer] is the leading provider of cloud-based platforms that power a seamless, end-to-end direct-to-patient healthcare experience. The name reflects our core strength: 'i' for robust data and technology infrastructure and 'x' for exceptional user experience. ixEngage by ixlayer seamlessly integrates with all healthcare ecosystem partners, connecting biopharma with patients in a user-centric way.

ixlayer [发音：I-X-layer] 是领先的基于云的平台提供商，助力实现无缝的端到端直接面向患者的医疗体验。名称反映了我们的核心优势：“i”代表强大的数据和技术基础设施，“x”代表卓越的用户体验。ixlayer 推出的 ixEngage 无缝集成所有医疗生态系统合作伙伴，以用户为中心的方式将生物制药与患者连接起来。

This proprietary technology accelerates the path to diagnoses, supports optimal care, drives operational efficiency, and improves health equity and outcomes for all. To date, ixlayer has activated over four million patient care journeys, simplifying the complex web of healthcare. Learn more at.

这项专有技术加快了诊断路径，支持最佳护理，提高运营效率，并改善所有人的健康公平性和结果。迄今为止，ixlayer已经启动了超过四百万次患者护理旅程，简化了复杂的医疗网络。欲了解更多信息，请访问。

www.ixlayer.com

www.ixlayer.com

.

。

About Ipsos

关于益普索

Ipsos is one of the largest market research and polling companies globally, operating in 90 markets and employing over 18,000 people.

益普索是全球最大的市场研究和民意调查公司之一，在90个市场开展业务，拥有超过18,000名员工。

Our passionately curious research professionals, analysts and scientists have built unique multi-specialist capabilities that provide true understanding and powerful insights into the actions, opinions and motivations of citizens, consumers, patients, customers or employees. Our 75 solutions are based on primary data from our surveys, social media monitoring, and qualitative or observational techniques..

我们充满热情、好奇心旺盛的研究人员、分析师和科学家建立了独特的多学科能力，能够真正理解并深入洞察公民、消费者、患者、客户或员工的行为、观点和动机。我们的75种解决方案基于来自我们的调查、社交媒体监控以及定性或观察技术的初步数据。

Our tagline 'Game Changers' sums up our ambition to help our 5,000 customers move confidently through a rapidly changing world.

我们的口号“变革者”概括了我们帮助5000名客户在瞬息万变的世界中自信前行的雄心。

Founded in

成立于

France

法国

in 1975, Ipsos has been listed on the Euronext Paris since

1975年，益普索自那时起已在巴黎泛欧交易所上市

July 1, 1999

1999年7月1日

. The company is part of the SBF 120 and Mid-60 indices and is eligible for the Deferred Settlement Service (SRD). ISIN code FR0000073298, Reuters ISOS.PA, Bloomberg IPS:FP

该公司是SBF 120和Mid-60指数的组成部分，并有资格参与延期结算服务（SRD）。ISIN代码为FR0000073298，路透社代码ISOS.PA，彭博代码IPS:FP。

www.ipsos.com

www.ipsos.com

Survey Methodology

调查方法论

These are some of the findings of an ixlayer patient survey, with data collection done by Ipsos. A total of n=414 individuals, ages 21+, with at least one of the following conditions was surveyed online between

以下是ixlayer患者调查的一些结果，数据收集由Ipsos完成。共有n=414名年龄在21岁及以上、至少符合以下条件之一的个体在线参与了调查，时间介于

January 6-24, 2025

2025年1月6日至24日

: asthma, COPD, type 2 diabetes, heart disease, psoriasis, or atopic dermatitis. Some quotas were placed around respondent age in order to achieve a nearly even split of baby boomer, Gen X, and millennial respondents. No weights were applied to the data, and the findings reflect the opinion of these survey respondents only. .

：哮喘、慢性阻塞性肺病、2型糖尿病、心脏病、牛皮癣或特应性皮炎。对受访者年龄设置了一些配额，以实现婴儿潮一代、X世代和千禧一代受访者的近乎平均分配。数据未加权，调查结果仅反映这些受访者的观点。

SOURCE ixlayer

来源 ixlayer

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗？

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用